Patients with unresected LA SCCHN (oropharynx [p16-negative only], hypopharynx, or larynx) were randomly assigned 1:1 to six cycles of oral xevinapant 200 mg/day or matched placebo (once daily on Days ...
Nearly half (45%) of head and neck cancer clinical trials registered from 2005 to 2021 were never published. Trials without statistically significant results and those that were considered incomplete ...
A simple blood test can detect head and neck cancers even 10 years before symptoms begin: Here's how
A groundbreaking blood test, HPV-DeepSeek, developed by Mass General Brigham researchers, offers early detection of HPV-associated head and neck cancers, potentially up to a decade before symptoms ...
Researchers at MUSC Hollings Cancer Center have discovered a potentially powerful weapon in the fight against head and neck cancers. The new drug, still in preclinical studies, attacks cancer cells ...
Human papilloma virus (HPV) causes around 70% of head and neck cancers in the United States, making it the most common cancer caused by the virus, with rates increasing each year. Unlike cervical ...
Researchers have reported results from the first-ever clinical trial of a new class of targeted therapy in pet cats with head and neck squamous cell carcinoma (HNSCC)—a cancer which is notoriously ...
Please provide your email address to receive an email when new articles are posted on . Researchers are investigating whether cannabis use can impact recovery from wounds associated with head and neck ...
Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study The following ...
Click to share on X (Opens in new window) X Click to share on Facebook (Opens in new window) Facebook Beavis and Butt-Head isn’t the kind of series that pays a lot of attention to how the duo have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback